HS-20093 + enzalutamide

HS-20093 + enzalutamide is a combination therapy composed of **HS-20093**, a novel B7-H3-targeted antibody-drug conjugate (ADC), and **enzalutamide**, an androgen receptor (AR) inhibitor. HS-20093 consists of a fully humanized anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload and is developed primarily for the treatment of a variety of advanced solid tumors, including small cell lung cancer, sarcoma, head and neck cancers, and esophageal squamous cell carcinoma. Enzalutamide is a small molecule non-steroidal antiandrogen approved for the treatment of prostate cancer, particularly metastatic castration-resistant prostate cancer, and works by competitively inhibiting the androgen receptor, thus blocking androgen signaling. The rationale behind combining HS-20093 with enzalutamide (though not specifically referenced in available studies) would be to leverage different mechanisms—immune-tumor targeting (via B7-H3 ADC) and hormone disruption (via AR antagonism)—to potentially achieve a synergistic anti-tumor effect in tumors expressing B7-H3 and dependent on androgen receptor signaling.